A citation-based method for searching scientific literature

Georgia Chenevix-Trench, Sue Healey, Sunil Lakhani, Paul Waring, Margaret Cummings, Ross Brinkworth, Amie M Deffenbaugh, Lynn Anne Burbidge, Dmitry Pruss, Thad Judkins, Tom Scholl, Anna Bekessy, Anna Marsh, Paul Lovelock, Ming Wong, Andrea Tesoriero, Helene Renard, Melissa Southey, John L Hopper, Koulis Yannoukakos, Melissa Brown, Douglas Easton, Sean V Tavtigian, David Goldgar, Amanda B Spurdle. Cancer Res 2006
Times Cited: 131







List of co-cited articles
738 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.
David E Goldgar, Douglas F Easton, Amie M Deffenbaugh, Alvaro N A Monteiro, Sean V Tavtigian, Fergus J Couch. Am J Hum Genet 2004
275
56

A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.
Douglas F Easton, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Richard J Wenstrup, Kristina Allen-Brady, Sean V Tavtigian, Alvaro N A Monteiro, Edwin S Iversen, Fergus J Couch,[...]. Am J Hum Genet 2007
313
41

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
554
32

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
27

Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Amanda B Spurdle, Sunil R Lakhani, Sue Healey, Suzanne Parry, Leonard M Da Silva, Ross Brinkworth, John L Hopper, Melissa A Brown, Davit Babikyan, Georgia Chenevix-Trench,[...]. J Clin Oncol 2008
61
42

Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Andrew D Spearman, Kevin Sweet, Xiao-Ping Zhou, Jane McLennan, Fergus J Couch, Amanda Ewart Toland. J Clin Oncol 2008
63
41

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
25

Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.
David E Goldgar, Douglas F Easton, Graham B Byrnes, Amanda B Spurdle, Edwin S Iversen, Marc S Greenblatt. Hum Mutat 2008
131
23

Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
A Osorio, R L Milne, E Honrado, A Barroso, O Diez, R Salazar, M de la Hoya, A Vega, J Benítez. Hum Mutat 2007
35
62

Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
S V Tavtigian, A M Deffenbaugh, L Yin, T Judkins, T Scholl, P B Samollow, D de Silva, A Zharkikh, A Thomas. J Med Genet 2006
475
21


Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Marcelo A Carvalho, Sylvia M Marsillac, Rachel Karchin, Siranoush Manoukian, Scott Grist, Ramona F Swaby, Turan P Urmenyi, Edson Rondinelli, Rosane Silva, Luis Gayol,[...]. Cancer Res 2007
91
20

Functional assays for classification of BRCA2 variants of uncertain significance.
Daniel J Farrugia, Mukesh K Agarwal, Vernon S Pankratz, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Linda Wadum, Kiley Johnson, Jennifer Mentlick, Sean V Tavtigian,[...]. Cancer Res 2008
89
21

Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
Kangjian Wu, Shannon R Hinson, Akihiro Ohashi, Daniel Farrugia, Patricia Wendt, Sean V Tavtigian, Amie Deffenbaugh, David Goldgar, Fergus J Couch. Cancer Res 2005
102
18

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
V Abkevich, A Zharkikh, A M Deffenbaugh, D Frank, Y Chen, D Shattuck, M H Skolnick, A Gutin, S V Tavtigian. J Med Genet 2004
124
16

Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
J Vallon-Christersson, C Cayanan, K Haraldsson, N Loman, J T Bergthorsson, K Brøndum-Nielsen, A M Gerdes, P Møller, U Kristoffersson, H Olsson,[...]. Hum Mol Genet 2001
131
16

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Amanda B Spurdle, Sue Healey, Andrew Devereau, Frans B L Hogervorst, Alvaro N A Monteiro, Katherine L Nathanson, Paolo Radice, Dominique Stoppa-Lyonnet, Sean Tavtigian, Barbara Wappenschmidt,[...]. Hum Mutat 2012
183
16

A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Noralane M Lindor, Lucia Guidugli, Xianshu Wang, Maxime P Vallée, Alvaro N A Monteiro, Sean Tavtigian, David E Goldgar, Fergus J Couch. Hum Mutat 2012
142
16

Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
Thaddeus Judkins, Brant C Hendrickson, Amie M Deffenbaugh, Kristilyn Eliason, Benoît Leclair, Michael J Norton, Brian E Ward, Dmitri Pruss, Thomas Scholl. Cancer Res 2005
49
28

Prediction and assessment of splicing alterations: implications for clinical testing.
Amanda B Spurdle, Fergus J Couch, Frans B L Hogervorst, Paolo Radice, Olga M Sinilnikova. Hum Mutat 2008
90
15

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
Encarna B Gómez García, Jan C Oosterwijk, Maarten Timmermans, Christi J van Asperen, Frans B L Hogervorst, Nicoline Hoogerbrugge, Rogier Oldenburg, Senno Verhoef, Charlotte J Dommering, Margreet G E M Ausems,[...]. Breast Cancer Res 2009
41
34

Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.
Logan C Walker, Phillip J Whiley, Fergus J Couch, Daniel J Farrugia, Sue Healey, Diana M Eccles, Feng Lin, Samantha A Butler, Sheila A Goff, Bryony A Thompson,[...]. Hum Mutat 2010
46
30

A full-likelihood method for the evaluation of causality of sequence variants from family data.
Deborah Thompson, Douglas F Easton, David E Goldgar. Am J Hum Genet 2003
88
14

Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
Ana Osorio, Miguel de la Hoya, Raquel Rodríguez-López, Angel Martínez-Ramírez, Alicia Cazorla, Juan José Granizo, Manel Esteller, Carmen Rivas, Trinidad Caldés, Javier Benítez. Int J Cancer 2002
88
14

Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Nebojsa Mirkovic, Marc A Marti-Renom, Barbara L Weber, Andrej Sali, Alvaro N A Monteiro. Cancer Res 2004
83
14

Functional impact of missense variants in BRCA1 predicted by supervised learning.
Rachel Karchin, Alvaro N A Monteiro, Sean V Tavtigian, Marcelo A Carvalho, Andrej Sali. PLoS Comput Biol 2007
47
25

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
628
12

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
12

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
12

Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
Paul K Lovelock, Amanda B Spurdle, Myth T S Mok, Daniel J Farrugia, Sunil R Lakhani, Sue Healey, Stephen Arnold, Daniel Buchanan, Fergus J Couch, Beric R Henderson,[...]. Breast Cancer Res 2007
48
25

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
11

Classification of BRCA1 missense variants of unknown clinical significance.
C M Phelan, V Dapic, B Tice, R Favis, E Kwan, F Barany, S Manoukian, P Radice, R B van der Luijt, B P M van Nesselrooij,[...]. J Med Genet 2005
75
14

Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
Kathleen Claes, Bruce Poppe, Eva Machackova, Ilse Coene, Lenka Foretova, Anne De Paepe, Ludwine Messiaen. Genes Chromosomes Cancer 2003
68
14


Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
L C Wu, Z W Wang, J T Tsan, M A Spillman, A Phung, X L Xu, M C Yang, L Y Hwang, A M Bowcock, R Baer. Nat Genet 1996
561
10

Assessment of functional effects of unclassified genetic variants.
Fergus J Couch, Lene Juel Rasmussen, Robert Hofstra, Alvaro N A Monteiro, Marc S Greenblatt, Niels de Wind. Hum Mutat 2008
80
12

Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Megan S Lee, Ruth Green, Sylvia M Marsillac, Nicolas Coquelle, R Scott Williams, Telford Yeung, Desmond Foo, D Duong Hau, Ben Hui, Alvaro N A Monteiro,[...]. Cancer Res 2010
98
10

A guide for functional analysis of BRCA1 variants of uncertain significance.
Gaël A Millot, Marcelo A Carvalho, Sandrine M Caputo, Maaike P G Vreeswijk, Melissa A Brown, Michelle Webb, Etienne Rouleau, Susan L Neuhausen, Thomas v O Hansen, Alvaro Galli,[...]. Hum Mutat 2012
85
11

A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
Lucia Guidugli, Vernon S Pankratz, Namit Singh, James Thompson, Catherine A Erding, Christoph Engel, Rita Schmutzler, Susan Domchek, Katherine Nathanson, Paolo Radice,[...]. Cancer Res 2013
71
14

Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
R Scott Williams, Daniel I Chasman, D Duong Hau, Benjamin Hui, Albert Y Lau, J N Mark Glover. J Biol Chem 2003
94
9

Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.
Joanna R Morris, Laurent Pangon, Chris Boutell, Toyomasa Katagiri, Nicholas H Keep, Ellen Solomon. Hum Mol Genet 2006
76
11

Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
A A Tesoriero, E M Wong, M A Jenkins, J L Hopper, M A Brown, G Chenevix-Trench, A B Spurdle, M C Southey. Hum Mutat 2005
42
21

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
R Hashizume, M Fukuda, I Maeda, H Nishikawa, D Oyake, Y Yabuki, H Ogata, T Ohta. J Biol Chem 2001
504
9

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
A C Antoniou, A P Cunningham, J Peto, D G Evans, F Lalloo, S A Narod, H A Risch, J E Eyfjord, J L Hopper, M C Southey,[...]. Br J Cancer 2008
302
9

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Sunil R Lakhani, Jorge S Reis-Filho, Laura Fulford, Frederique Penault-Llorca, Marc van der Vijver, Suzanne Parry, Timothy Bishop, Javier Benitez, Carmen Rivas, Yves-Jean Bignon,[...]. Clin Cancer Res 2005
445
9

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
582
9

Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
Suhwan Chang, Kajal Biswas, Betty K Martin, Stacey Stauffer, Shyam K Sharan. J Clin Invest 2009
58
15

Characterization of BRCA1 ring finger variants of uncertain significance.
Kevin Sweet, Leigha Senter, Robert Pilarski, Lai Wei, Amanda Ewart Toland. Breast Cancer Res Treat 2010
20
45

Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
R Scott Williams, Megan S Lee, D Duong Hau, J N Mark Glover. Nat Struct Mol Biol 2004
176
8

BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
Sandro Malacrida, Simona Agata, Monia Callegaro, Cinzia Casella, Daniela Barana, Maria C Scaini, Siranoush Manoukian, Cristina Oliani, Paolo Radice, Monica Barile,[...]. J Clin Oncol 2008
51
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.